-
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
•
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for the first half of 2023, following the completion of the separation of its consumer healthcare spinoff, Kenvue (NYSE: KVUE), into an independent company. The document reveals that H1 2023 global sales reached USD 42.4 billion,…
-
Johnson & Johnson Completes Spinoff of Kenvue as Independent Company
•
Global healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has completed the separation of its consumer healthcare business, Kenvue (NYSE: KVUE), as an independent entity. The transaction involved the exchange of 191 million J&J shares for 1.5 billion shares of Kenvue, with J&J retaining a 9.5% stake in the newly…
-
Johnson & Johnson’s Kenvue IPO Raises USD 3.8 Billion, Marking Year’s Largest US IPO
•
US healthcare giant Johnson & Johnson (J&J, NYSE: JNJ) has announced the initial public offering (IPO) of 173 million shares by its consumer health spin-off company Kenvue to the New York Stock Exchange (NYSE), raising a staggering USD 3.8 billion. This transaction has secured its place as the biggest IPO…
